Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.

导出 LinkOut

翻译打印收藏纠错

作者： W Michael,Seganish ^[1] ; William T,McElroy ^[2] ; R Jason,Herr ^[3] ; Stephanie,Brumfield ^[2] ; William J,Greenlee ^[2] ; James,Harding ^[3] ; Venukrishnan,Komanduri ^[4] ; Julius,Matasi ^[2] ; Koraboina Chandra,Prakash ^[4] ; Deen,Tulshian ^[2] ; Jinhai,Yang ^[3] ; Larry,Yet ^[3] ; Kristine,Devito ^[5] ; James,Fossetta ^[6] ; Charles G,Garlisi ^[5] ; Daniel,Lundell ^[6] ; Xiaoda,Niu ^[5] ; Christopher,Sondey ^[5]

作者单位： Discovery Chemistry, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States. Electronic address: william.seganish@merck.com. ^[1] Discovery Chemistry, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States. ^[2] Medicinal Chemistry Department, Albany Molecular Research, Inc. (AMRI), 26 Corporate Circle, Albany, NY 12203, United States. ^[3] Medicinal Chemistry Department, AMRI Singapore Research Centre, 61 Science Park Road, #05-01, The Galen, Science Park III, Singapore 117525, Singapore. ^[4] In Vitro Pharmacology, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States. ^[5] Respiratory and Immunology, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States. ^[6]

关键词 Aminopyrimidine IRAK4 Inflammation Kinase Structure activity relationships